×

Csl Limited

Over a century ago in Melbourne, Australia, we made a promise to save lives and protect the health of people who were stricken with a range of serious and chronic medical conditions. Today, as a leading global biotech company, that same promise has never been stronger. We develop and deliver innovative biotherapies and influenza vaccines that save lives, and help people with life-threatening medical conditions live full lives. We are driven by our deep passion to serve hundreds of thousands of patients and other stakeholders around the world.

ASX Code
CSL

Sector
Pharmaceuticals- Biotechnology & Life Sciences

Website
https://www.csl.com/

Spotlight Videos

Deep dive into CSL, NUF & IPH and charts on China risks

November 22, 2023 - by Finance News Network

Fund Manager Chris Pedersen looks at CSL (ASX:CSL), Nufarm (ASX:NUF), IPH (ASX:IPH) and charts on China risks.

Watch Now

Airlie FM April 2023 Quarterly Update

April 25, 2023 - by Airlie Funds Management

Airlie FM's Emma Fisher provides her views on the current market environment and discusses her recent trip to Europe where she visited the HQs of key holdings CSL and QBE Insurance.

Watch Now

News

CSL posts strong profit but investors unimpressed

August 13, 2024 - by Glenn Dyer

Investors didn’t like the annual results and outlook from Australia’s home-grown “Big Pharma”, CSL (ASX:CSL).

Read More

Heated audience at CSL’s AGM

October 11, 2023 - by Glenn Dyer

CSL's (ASX:CSL) Annual General Meeting in Melbourne on Wednesday turned into a heated discussion regarding executive pay and a declining share price, casting a shadow over the reaffirmation of guidance for the upcoming year.

Read More

Shareholders to receive more from CSL as revenue and earnings surge

August 15, 2023 - by Glenn Dyer

Shareholders of the blood products giant CSL (ASX:ASX) are set to benefit as the company increased its revenue and earnings in the year leading up to June 30.

Read More

Market Smells Blood, Gives CSL a Whack

June 14, 2023 - by Glenn Dyer

Shares in pharma giant CSL took a hit yesterday after it revealed a larger than forecast loss from currency movements for its FY2022-23.

Read More

Industrials Intel: JHX, CSL, ANN

February 14, 2023 - by Glenn Dyer

A bit of a mixed bag from three of our big industrial companies on Tuesday, with James Hardie and Ansell both taking a recent earnings hit but old reliable CSL still going strong.

Read More

Bourse Discourse: CSL, EDV

October 17, 2022 - by Glenn Dyer

One could almost be excused for thinking we are in the middle of a roaring bull market in the context of very upbeat presentations on Monday from CSL and Endeavour Group.

Read More

Stock Snippets: CRN, CSL

October 12, 2022 - by Glenn Dyer

Word of possible takeover talks with Peabody Energy sent shares in coal miner Coronado charging Wednesday, while CSL also brought some good news to the market.

Read More

Flu Division Helps Immunise CSL’s Bottom Line

August 17, 2022 - by Glenn Dyer

Lower blood plasma collection volumes meant CSL had a 6% fall in full-year profit, but a bumper year for the Seqirus flu vaccine business pushed revenues higher for the year to June.

Read More

CSL – Macquarie rates the stock as Outperform

July 4, 2022 - by Broker News

The Outperform rating and target price of $312.00 are retained.

Read More

CSL – Macquarie rates the stock as Outperform

June 17, 2022 - by Broker News

The broker retains an Outperform rating and lowers the target to $312.00 from $327.25.

Read More